MedTrace Logo

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

NCT07225036 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

Conditions

  • Low-Dose Liver Radiation (LD-LRT)
  • Non Small Cell Lung Cancer
  • Melanoma
  • Liver Metastases

Interventions

RADIATION

LD-LRT

Low-dose radiation to the liver the week prior to Cycles 1, 2 and 3 of standard of care immunotherapy treatment.

Sponsors & Collaborators

  • Jordan Kharofa

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2027-06-15
Completion
2029-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07225036 on ClinicalTrials.gov